Page 504 of 857: studies 5,031 to 5,040 of 8,563, newest first. Back to the addiction overview
European Psychiatry April 1, 2021 S. Torres 2 citations
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations. In 1950, after LSD’s discovery by Hofmann, psychedelics enjoyed a short-lived relationship with psychiatry, before prohibitive legislature emerging in response to the recreational use in the mid-1960s....
European Psychiatry April 1, 2021 Nelson Descalço, Ana Beatriz Medeiros, Cátia Fernandes Santos et al. 1 citation
Introduction Psilocybin is a naturally occurring plant alkaloid in mushrooms and a prodrug of psilocin. It is a serotonin receptor (5-HT2A) agonist and known psychedelic, with similar hallucinatory properties to lysergic acid diethylamide (LSD). It has been identified as a safe and effective option in treatment-resistant depression. Literature focus mainly on its use on depressive but its...
Archives of Toxicology April 1, 2021 Young-Jung Kim, Shi-Xun Ma, Kwang-Hyun Hur et al. 10 citations
2C (2C-x) is the general name for the family of phenethylamines containing two methoxy groups at the 2 and 5 positions of the benzene ring. The abuse of 2C family drugs has grown rapidly, although the abuse potential and neurotoxic properties of 2C drugs have not yet been fully investigated. In this study, we investigated the abuse potential and neurotoxicity of...
Psychiatric News March 31, 2021 Stanley N. Caroff 1 citation
Recently, a movement reviving psychedelic drugs has emerged among physicians, echoed by activists like Michael Pollan, who promoted psychedelics for treating a variety of conditions and for "the betterment of well people" in his latest book, How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence. Pollan...
Journal of Psychopharmacology March 28, 2021 Mitch Earleywine, Luna F. Ueno, Maha N. Mian et al. 36 citations
Background: Despite tetrahydrocannabinol (THC)’s reputation for creating dramatic effects at high doses, empirical work rarely addresses cannabis’s impact on subjective responses common to the tryptamine psychedelics. We focused on these effects because they have preceded and covaried with the therapeutic impact of psilocybin in previous work. Aims: The current study examined if self-reported...
Psychocentrum Review March 25, 2021 Ramchandra Lamba, Sona Budaniya, Rajendera Kumar Acharya et al.
Use of cannabis for recreational, religious and cultures has been prevalent since ancient times. It is one of the commonest used illicit substance. While not all cannabis users develop psychiatric problems, heavy cannabis use may increase the risk of cognitive abnormalities, psychotic illness and mood disorders. This research aimed to evaluate severity of various psychotic symptoms in relation...
Frontiers in Pharmacology March 25, 2021 Hannes Kettner, Fernando E. Rosas, C. Timmermann et al. 205 citations
Background: Recent years have seen a resurgence of research on the potential of psychedelic substances to treat addictive and mood disorders. Historically and contemporarily, psychedelic studies have emphasized the importance of contextual elements ('set and setting') in modulating acute drug effects, and ultimately, influencing long-term outcomes. Nevertheless, current small-scale clinical and...
Frontiers in Psychiatry March 24, 2021 George Savulich, Owen Bowden-Jones, Robert Stephenson et al.
Novel psychoactive substances (NPS) are popular "club/party" drugs that first attracted attention in the UK in 2009 and remained legal until the 2016 Psychoactive Substances Act criminalized their distribution. Unlike "traditional" illicit drugs, very little is known about the influence of their analogs on neuropsychological functioning. We characterized the cognitive and emotional profile of...
Biology March 24, 2021 Nunzia La Maida, Esther Papaseit, Lucía Martínez de Soto et al. 14 citations
Synthetic cannabinoids (SCs) are one of the most frequent classes of new psychoactive substances monitored by the EU Early Warning System and World Health Organization. UR-144 is a SC with a relative low affinity for the CB1 receptor with respect to that for the CB2 receptor. As with other cannabinoid receptor agonists, it has been monitored by the EU Early Warning System since 2012 for severe...
Frontiers in Pharmacology March 23, 2021 Joseph Tay Wee Teck, Alexander Baldacchino, Lauren Gibson et al.
Healthcare innovation has never been more important as it is now when the world is facing up to the unprecedented challenges brought by the COVID-19 pandemic. Within addictions services in Scotland, the priority has been to tackle our rising drug related death rate by maintaining and improving access to treatment while protecting frontline workers and managing operational challenges as a result...